文献速递神经肿瘤

立体定向放射外科治疗WHO I级后颅窝脑膜瘤:长期结局与体积评估

Stereotactic radiosurgery for WHO grade I posterior fossa meningiomas: long-term outcomes with volumetric evaluation.
PubMed 文献 · J Neurosurg · 2018-01-05

该回顾性分析纳入120例WHO I级后颅窝脑膜瘤患者,接受单次立体定向放射外科治疗。中位边缘剂量15 Gy,中位影像随访72个月,总体肿瘤控制率89.2%。体积分析显示治疗后3年肿瘤体积变化可预测5年和10年的体积变化及肿瘤控制。

要点

  • 立体定向放射外科治疗WHO I级后颅窝脑膜瘤的总体肿瘤控制率为89.2%(107例)。
  • 边缘剂量≥16 Gy组2-10年无进展生存率为100%,≤12 Gy组10年降至56.9%。
  • 治疗后3年体积变化可预测5年(R²=0.756,p<0.001)和10年(R²=0.421,p=0.001)的肿瘤控制。

核心结论

  • 立体定向放射外科作为初始或辅助治疗,是WHO I级后颅窝脑膜瘤的持久治疗选择,肿瘤控制率高且治疗后神经功能缺损发生率低。
  • 治疗后3年的病灶体积反应可预测5年和10年的长期反应。

研究设计与样本

  • 回顾性分析前瞻性维护的IRB批准数据库,纳入WHO I级后颅窝脑膜瘤接受单次立体定向放射外科治疗且至少3次随访MRI的患者,共120例。
  • 对放射外科扫描及每次随访扫描进行体积分析,采用逐层面积计算和梯形法则数值积分。

主要发现

  • 120例患者中76.6%(92例)为女性,中位年龄61岁(12-88岁);65%(78例)以立体定向放射外科为首选治疗,28.3%(34例)此前接受1次切除,6.7%(8例)接受2次或以上切除,1例曾接受放疗。
  • 治疗时中位肿瘤体积4.0 cm³(0.4-40.9 cm³),中位边缘剂量15 Gy(8-20 Gy);中位临床随访79.5个月(15-224个月),中位影像随访72个月(6-213个月)。
  • 边缘剂量≥16 Gy组治疗后2-10年无进展生存率为100%;13-15 Gy组2、4、6、8、10年无进展生存率分别为97.5%、97.5%、93.4%、93.4%、93.4%;≤12 Gy组分别为95.8%、82.9%、73.2%、56.9%、56.9%。
  • 总体肿瘤控制率89.2%(107例);治疗后神经系统症状改善23.3%(28例),稳定70.8%(85例),恶化5.8%(7例)。
  • 治疗后3年肿瘤体积变化预测5年体积变化和肿瘤控制(R²=0.756,p<0.001)及10年(R²=0.421,p=0.001);1-5年肿瘤反应预测5-10年肿瘤反应(R²=0.636,p<0.001)。

临床怎么用

  • 作者认为立体定向放射外科作为初始或辅助治疗,是WHO I级后颅窝脑膜瘤的持久治疗选择。
  • 作者指出治疗后3年的病灶体积反应可预测5年和10年的长期反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVEResearch over the past 2 decades has been characterizing the role of stereotactic radiosurgery (SRS) in the treatment of benign intracranial tumors, including meningiomas. However, few studies have examined the long-term outcomes of SRS treatment for posterior fossa meningiomas (PFMs). Furthermore, previous studies have typically used single diameter measurements when reporting outcomes, which can yield misleading results. The authors describe the use of SRS in the treatment of benign WHO grade I PFMs and correlate volumetric analysis with long-term outcomes.METHODSThis study is a retrospective analysis of a prospectively maintained IRB-approved database. Inclusion criteria were a diagnosis of WHO grade I PFM with subsequent treatment via single-session SRS and a minimum of 3 follow-up MRI studies available. Volumetric analysis was performed on the radiosurgical scan and each subsequently available follow-up scan by using slice-by-slice area calculations of the meningioma and numerical integration with the trapezoid rule.RESULTSThe final cohort consisted of 120 patients, 76.6% (92) of whom were female, with a median age of 61 years (12-88 years). Stereotactic radiosurgery was the primary treatment for 65% (78) of the patients, whereas 28.3% (34) had 1 resection before SRS treatment and 6.7% (8) had 2 or more resections before SRS. One patient had prior radiotherapy. Tumor characteristics included a median volume of 4.0 cm3 (0.4-40.9 cm3) at treatment with a median margin dose of 15 Gy (8-20 Gy). The median clinical and imaging follow-ups were 79.5 (15-224) and 72 (6-213) months, respectively. For patients treated with a margin dose ≥ 16 Gy, actuarial progression-free survival rates during the period 2-10 years post-SRS were 100%. In patients treated with a margin dose of 13-15 Gy, the actuarial progression-free survival rates at 2, 4, 6, 8, and 10 years were 97.5%, 97.5%, 93.4%, 93.4%, and 93.4%, respectively. Those who were treated with ≤ 12 Gy had actuarial progression-free survival rates of 95.8%, 82.9%, 73.2%, 56.9%, and 56.9% at 2, 4, 6, 8, and 10 years, respectively. The overall tumor control rate was 89.2% (107 patients). Post-SRS improvement in neurological symptoms occurred in 23.3% (28 patients), whereas symptoms were stable in 70.8% (85 patients) and worsened in 5.8% (7 patients). Volumetric analysis demonstrated that a change in tumor volume at 3 years after SRS reliably predicted a volumetric change and tumor control at 5 years (R2 = 0.756) with a p < 0.001 and at 10 years (R2 = 0.421) with a p = 0.001. The authors also noted that the 1- to 5-year tumor response is predictive of the 5- to 10-year tumor response (R2 = 0.636, p < 0.001).CONCLUSIONSStereotactic radiosurgery, as an either upfront or adjuvant treatment, is a durable therapeutic option for WHO grade I PFMs, with high tumor control and a low incidence of post-SRS neurological deficits compared with those obtained using alternate treatment modalities. Lesion volumetric response at the short-term follow-up of 3 years is predictive of the long-term response at 5 and 10 years.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Patibandla MR, Lee CC, Tata A, et al. Stereotactic radiosurgery for WHO grade I posterior fossa meningiomas: long-term outcomes with volumetric evaluation. J Neurosurg. 2018. PMID: 29303453. doi:10.3171/2017.6.JNS17993

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。